<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7230963</article-id><article-id pub-id-type="doi">10.3390/jcm9041073</article-id><article-id pub-id-type="publisher-id">jcm-09-01073</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Clinical Characteristics and Predictors of Mortality in Critically Ill Influenza Adult Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hsu</surname><given-names>Jui-Chi</given-names></name><xref ref-type="aff" rid="af1-jcm-09-01073">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Ing-Kit</given-names></name><xref ref-type="aff" rid="af1-jcm-09-01073">1</xref><xref ref-type="aff" rid="af2-jcm-09-01073">2</xref><xref rid="c1-jcm-09-01073" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Wen-Chi</given-names></name><xref ref-type="aff" rid="af1-jcm-09-01073">1</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yi-Chun</given-names></name><xref ref-type="aff" rid="af1-jcm-09-01073">1</xref></contrib><contrib contrib-type="author"><name><surname>Tsai</surname><given-names>Ching-Yen</given-names></name><xref ref-type="aff" rid="af1-jcm-09-01073">1</xref></contrib></contrib-group><aff id="af1-jcm-09-01073"><label>1</label>Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan; <email>b9602048@cgmh.org.tw</email> (J.-C.H.); <email>heteyland@cgmh.org.tw</email> (W.-C.H.); <email>sonice83@cgmh.org.tw</email> (Y.-C.C.); <email>greenswallow822@yahoo.com.tw</email> (C.-Y.T.)</aff><aff id="af2-jcm-09-01073"><label>2</label>Department of Internal Medicine, Chang Gung University Medical College, Tao-Yuan 330, Taiwan</aff><author-notes><corresp id="c1-jcm-09-01073"><label>*</label>Correspondence: <email>leee@cgmh.org.tw</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>4</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2020</year></pub-date><volume>9</volume><issue>4</issue><elocation-id>1073</elocation-id><history><date date-type="received"><day>07</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>07</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Severe influenza is associated with high morbidity and mortality. The aim of this study was to investigate the factors affecting the clinical outcomes of critically ill influenza patients. In this retrospective study, we enrolled critically ill adult patients with influenza at the Kaohsiung Chang Gung Memorial Hospital in Taiwan. We evaluated the demographic, clinical, and laboratory findings and examined whether any of these measurements correlated with mortality. We then created an event-based algorithm as a simple predictive tool using two variables with statistically significant associations with mortality. Between 2015 and 2018, 102 critically ill influenza patients (median age, 62 years) were assessed; among them, 41 (40.1%) patients died. Of the 94 patients who received oseltamivir therapy, 68 (72.3%) began taking oseltamivir 48 h after the onset of illness. Of the 102 patients, the major influenza-associated complications were respiratory failure (97%), pneumonia (94.1%), acute kidney injury (65.7%), adult respiratory distress syndrome (ARDS) (51%), gastrointestinal bleeding (35.3%), and bacteremia (16.7%). In the multivariate regression model, high lactate levels, ARDS, acute kidney injury, and gastrointestinal bleeding were independent predictors of mortality in critically ill influenza patients. The optimal lactate level cutoff for predicting mortality was 3.7 mmol/L with an area under curve of 0.728. We constructed an event-associated algorithm that included lactate and ARDS. Fifteen (75%) of 20 patients with lactate levels 3.7 mmol/L and ARDS died, compared with only 1 (7.7%) of 13 patients with normal lactate levels and without ARDS. We identified clinical and laboratory predictors of mortality that could aid in the care of critically ill influenza patients. Identification of these prognostic markers could be improved to prioritize key examinations that might be useful in determining patient outcomes. </p></abstract><kwd-group><kwd>severe influenza</kwd><kwd>pneumonia</kwd><kwd>acute respiratory distress syndrome</kwd><kwd>lactate</kwd><kwd>mortality</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-jcm-09-01073"><title>1. Introduction</title><p>Influenza is an acute viral respiratory infection caused by different types of influenza viruses: influenza A, B, and C [<xref rid="B1-jcm-09-01073" ref-type="bibr">1</xref>]. Influenza A subtypes H1N1, H3N2, and influenza B are the most common causes of human influenza [<xref rid="B1-jcm-09-01073" ref-type="bibr">1</xref>]. The illness is usually mild and characterized by a sudden onset of fever, cough, sore throat, runny nose, headache, myalgia, and malaise [<xref rid="B1-jcm-09-01073" ref-type="bibr">1</xref>]. However, the virus can cause severe illness or even death, especially in high-risk individuals such as young children, the elderly, patients with certain comorbid chronic diseases, and immunocompromised patients [<xref rid="B2-jcm-09-01073" ref-type="bibr">2</xref>,<xref rid="B3-jcm-09-01073" ref-type="bibr">3</xref>]. Annually, the World Health Organization estimated that global influenza epidemics result in 3 to 5 million cases of severe illness and 290,000 to 650,000 deaths [<xref rid="B4-jcm-09-01073" ref-type="bibr">4</xref>,<xref rid="B5-jcm-09-01073" ref-type="bibr">5</xref>]. In 2009, a swine-origin influenza A (pandemic 2009 A/H1N1; pdm09 A/H1) emerged and rapidly caused a global pandemic [<xref rid="B6-jcm-09-01073" ref-type="bibr">6</xref>]. Remarkably, from 12 April 2009 to 10 April 2010, there were 60.8 million cases and 12,469 deaths in the United States due to pdm09 A/H1 [<xref rid="B7-jcm-09-01073" ref-type="bibr">7</xref>]. </p><p>Severe complicated influenza has a significantly high mortality and morbidity [<xref rid="B8-jcm-09-01073" ref-type="bibr">8</xref>,<xref rid="B9-jcm-09-01073" ref-type="bibr">9</xref>]. Secondary bacterial pneumonia and acute respiratory distress syndrome (ARDS) are some of the common pulmonary complications of influenza, often followed by grave outcomes [<xref rid="B10-jcm-09-01073" ref-type="bibr">10</xref>]. In addition to pulmonary complications, extra-pulmonary complications such as meningoencephalitis, myocarditis, and rhabdomyolysis have also been reported to be associated with either influenza A or B [<xref rid="B11-jcm-09-01073" ref-type="bibr">11</xref>,<xref rid="B12-jcm-09-01073" ref-type="bibr">12</xref>,<xref rid="B13-jcm-09-01073" ref-type="bibr">13</xref>]. While early antiviral therapy may reduce complications of influenza [<xref rid="B14-jcm-09-01073" ref-type="bibr">14</xref>,<xref rid="B15-jcm-09-01073" ref-type="bibr">15</xref>,<xref rid="B16-jcm-09-01073" ref-type="bibr">16</xref>], the majority of patients tend to delay seeking medical care and timely diagnosis, leading to the subsequent development of influenza-associated complications, particularly in the elderly and those with comorbid illnesses. Hence, key clinical data are crucial pieces of information that can help clinicians deliver the necessary management to critically ill influenza patients in a timely manner. In the present study, we reviewed the entire clinical course and laboratory data of critically ill patients with influenza and then explored the risk factors independently associated with death as well as constructed a valuable event associated algorithm to help in the assessment of risk of death.</p></sec><sec sec-type="methods" id="sec2-jcm-09-01073"><title>2. Methods</title><sec id="sec2dot1-jcm-09-01073" sec-type="subjects"><title>2.1. Study Design and Patients</title><p>We retrospectively studied all critically ill adult patients (aged &#x02265;18 years) with laboratory-confirmed influenza infection admitted between 2015 and 2018, at the Kaohsiung Chang Gung Memorial Hospital, a 2700-bed primary care and tertiary referral medical center that included 5 adult medical and 4 surgical intensive care units (ICUs) in Taiwan. Included critically ill influenza patients were those admitted to an ICU, or those with complications of lower respiratory tract infection and/or multiorgan failure, or those requiring mechanical ventilation during hospitalization. Individuals were excluded from the study if they are &#x0003c;18 years of age; if they are treated as outpatients; or if they had mild flu-like symptoms. Confirmation of influenza virus infection required a positive finding in the respiratory specimen (nasopharyngeal swab and/or pharyngeal swab) by one or more of the following methods: rapid influenza diagnostic test (Formosa One Sure Flu A/B Rapid Test Kit), isolation of the virus in tissue-cell culture (Madin-Darby canine kidney (MDCK) cell line), or reverse-transcriptase&#x02013;polymerase chain reaction (RT-PCR) (QiAamp Viral RNA Mini Kit; TAIGEN Bioscience Corporation, Taiwan). The choice of diagnostic test (rapid influenza diagnostic test, virus isolation or RT-PCR) for confirming influenza was based on the individual physicians&#x02019; judgment.</p></sec><sec id="sec2dot2-jcm-09-01073"><title>2.2. Data Collection and Definitions</title><p>A standardized form for clinical data collection was designed. The data were mainly retrieved from the hospital&#x02019;s electronic medical records and were supplemented by a secondary manual search. The following data were collected: demographic characteristics, underlying medical conditions, clinical signs and symptoms, antiviral treatment course (oseltamivir or peramivir therapy), results of laboratory tests and radiography findings at the time of presentation and during the entire clinical course, in-hospital complications, and fatality.</p><p>Acute respiratory failure was defined as arterial partial pressure of oxygen (PaO<sub>2</sub>) &#x0003c;60 mmHg in ambient air, or tachypnea &#x0003e;30/min. ARDS was defined as acute respiratory distress characterized by bilateral pulmonary consolidation and severe hypoxemia (PaO<sub>2</sub>/Fraction of inspired oxygen ratio &#x0003c;300 mmHg) in the absence of evidence for cardiogenic pulmonary edema [<xref rid="B17-jcm-09-01073" ref-type="bibr">17</xref>]. Fulminant hepatitis meant alanine aminotransferase levels (ALT) greater than 16.6 &#x000b5;kat/L. Acute kidney injury was defined as a rapid increase in the serum creatinine level to &#x0003e;44.2 &#x000b5;mol/L compared with that at presentation. Rhabdomyolysis was defined as a five-fold increase in the serum concentrations of creatine phosphokinase above the upper limit of the normal range (reference value, 0.2&#x02013;2.2 &#x000b5;kat/L), with &#x0003e;95% creatine phosphokinase-muscle fraction. Meningoencephalitis was defined as an altered mental status, fulfilling at least 2 of the following criteria: (1) fever, (2) seizure, (3) focal neurologic signs, (4) abnormality of cerebrospinal fluid, (5) neuroimaging suggestive of encephalitis, and (6) abnormal findings on electroencephalography consistent with encephalitis [<xref rid="B18-jcm-09-01073" ref-type="bibr">18</xref>]. A galactomannan cutoff optical density index of &#x0003e;0.5 was used to define positivity for serum and bronchoalveolar lavage samples [<xref rid="B19-jcm-09-01073" ref-type="bibr">19</xref>,<xref rid="B20-jcm-09-01073" ref-type="bibr">20</xref>]. Mortality was defined as death occurring during the hospital stay for influenza.</p></sec><sec id="sec2dot3-jcm-09-01073"><title>2.3. Statistical Analysis</title><p>To analyze the predictors of mortality among critically ill influenza patients, we initially compared demographic, clinical characteristics, and laboratory findings as well as complications of survivors and nonsurvivors using Fisher&#x02019;s exact test for categorical variables and Mann-Whitney <italic>U</italic> test for numerical variables. The differences were considered significant at <italic>p</italic> &#x0003c; 0.05. Significant variables in the univariate analyses were entered into a multivariate logistic regression model to identify independent predictors of mortality in critically ill influenza patients. We used receiver operating characteristic curves (ROC) to select cutoff points for independent numerical predictors according to visual assessment of the highest sensitivity and specificity. We then created an event-based algorithm as a simple predictive tool using 2 variables with statistically significant associations with mortality (<italic>p</italic> value less than or equal to 0.001) in the multivariate model. Data were entered and analyzed using the Statistical Package for the Social Sciences statistical software (version 19.0; SPSS Inc., Chicago, IL, USA).</p></sec></sec><sec sec-type="results" id="sec3-jcm-09-01073"><title>3. Results</title><sec id="sec3dot1-jcm-09-01073"><title>3.1. Patient Characteristics</title><p>In total, 102 critically ill patients (97% in medical ICUs and 3% in surgical ICUs) comprising 62 men and 40 women, with a median age of 62 years with laboratory-confirmed influenza virus infection were assessed. The median time from illness onset to hospital presentation was three days (range, 1&#x02013;14).</p><p>Among the 102 patients, three did not receive antiviral therapy (either oseltamivir or peramivir). Of the 99 patients who received antiviral therapy, 89 patients received oseltamivir and five received peramivir; five patients received both oseltamivir and peramivir during their hospitalization. Of the 94 patients who received oseltamivir therapy, 68 (72.3%) began taking oseltamivir 48 h after the onset of illness. Among the 10 patients who received peramivir, 60% received antiviral therapy 48 h after the onset of symptoms. Among 102 patients, influenza A virus was detected in 77 (75.5%) patients (33.3% for pdm09 A/H1, 7.8% for H3N2 and 28.4% for untypable influenza A), influenza B virus in 24 (23.5%), and concurrent influenza A (untypable) and influenza B in 1 (0.9%). The clinical characteristics of the included patients are summarized in <xref rid="jcm-09-01073-t001" ref-type="table">Table 1</xref> and <xref rid="jcm-09-01073-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec3dot2-jcm-09-01073"><title>3.2. Laboratory Testing</title><p>The median white blood cell and platelet counts on admission were 7.9 &#x000d7; 10<sup>9</sup>/L and 156.5 &#x000d7; 10<sup>9</sup>/L, respectively. Regarding the laboratory data during hospitalization, the median highest white blood cell and platelet counts and creatinine, ALT, creatine kinase, C-reactive protein, and lactate concentrations were 16.8 &#x000d7; 10<sup>9</sup>/L, 101.5 &#x000d7; 10<sup>9</sup>/L, 183 &#x000b5;mol/L, 1.5 &#x000b5;kat/L (96 patients with data available), 5.5 &#x000b5;kat/L (35 patients with data available), 213.6 mg/L (100 patients with data available), and 3.1 mmol/L (90 patients with available data), respectively. Five (21.7%) of the 23 patients with available data showed serum galactomannan index of &#x0003e;0.5. Six patients underwent bronchoscopy and two had bronchoalveolar lavage fluid galactomannan index of 5.09 and 5.57 with fatal outcomes. <italic>Stenotrophomonas maltophilia</italic> was isolated from bronchoalveolar lavage specimen in one patient. Urinary <italic>Streptococcus</italic> antigen was detected in 3 of the 41 patients with available data. The laboratory characteristics of the included patients are shown in <xref rid="jcm-09-01073-t003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec3dot3-jcm-09-01073"><title>3.3. Complications</title><p><xref rid="jcm-09-01073-t004" ref-type="table">Table 4</xref> shows the in-hospital complications of the patients during the entire clinical course. The five common complications were respiratory failure (97%), pneumonia (94.1%), acute kidney injury (65.7%), ARDS (51%), and gastrointestinal bleeding (35.3%). Of 59 patients with data available, the median Sequential Organ Failure Assessment score was 6 (range, 2&#x02013;16). All of the 102 patients were required to be mechanically ventilated, and among them, 90 (88.2%) were ventilated invasively and 12 (11.7%) noninvasively. The median time from illness onset to acute respiratory failure was four days (range, 1&#x02013;27). Inotropes or vasopressors were used in 44 (43.1%) patients. Ninety-eight (96.1%) patients were admitted to the ICU. Four patients did not admit to ICU; of these, three patients died before ICU admission and the other one improved tachypnea after managed by noninvasive ventilation. </p><p>Extracorporeal membrane oxygenation (ECMO) was initiated for the treatment of refractory hypoxemia, hypercapnia, or both, which occurred despite invasive mechanical ventilation. Seventeen (median age 58 years; range, 24&#x02013;65) patients with severe influenza-associated ARDS were treated with ECMO, of whom 15 (88.2%) patients had influenza A virus and 2 (11.7%) had influenza B virus infection. The median duration of ECMO support was nine (range, 9&#x02013;25) days. Of the 17 patients with influenza-associated ARDS who received ECMO treatment, 12 (70.5%) died. In the 12 patients who died, acute kidney injury (<italic>n</italic> = 10), gastrointestinal bleeding (<italic>n</italic> = 8), rhabdomyolysis (<italic>n</italic> = 4), pneumothorax (<italic>n</italic> = 2), intracranial hemorrhage (<italic>n</italic> = 1), and fulminant hepatitis (<italic>n</italic> = 1) were the most common conditions contributing to death. </p><p>Among the 17 bacteremia patients, five (29.4%) patients had bacteremia (<italic>Staphylococcus aureus</italic> in 3, <italic>Pseudomonas aeruginosa</italic> in one, and <italic>Actinomyces oris</italic> and <italic>Streptococcus salivarius</italic> in one) within 48 h after hospitalization. Twelve patients experienced bacteremia after 48 h admission including <italic>Staphylococcus aureus</italic> (<italic>n</italic> = 3), Enterococcus species (<italic>n</italic> = 3), <italic>Stenotrophomonas maltophilia</italic> (<italic>n</italic> = 2), viridans streptococcus (<italic>n</italic> = 1), and <italic>Acinetobacter pittii</italic> (<italic>n</italic> = 1). <italic>Staphylococcus aureus</italic> (35.3%) (16.7% were methicillin resistant) and Enterococcus species (17.6%) were the most frequently isolated bacteria from blood cultures.</p></sec><sec id="sec3dot4-jcm-09-01073"><title>3.4. Outcomes</title><p>Of the 102 patients, 41 (median age, 61 [range, 24&#x02013;93] years) died, with an overall mortality rate of 40.1%. The median duration of illness before death was 18.5 (range, 2&#x02013;53) days. Nine patients (21.9%) died within seven days after symptom onset. Of 41 deceased patients, 80.5% had influenza A virus and 19.5% had influenza B virus infection. Of the 38 deceased patients who received oseltamivir treatment, 76.3% of patients received oseltamivir more than 48 h after onset of the illness (<xref rid="jcm-09-01073-t004" ref-type="table">Table 4</xref>). Among the 41 deceased patients, pneumonia developed in 39 (95.1%) patients, acute kidney injury in 33 (80.5%), ARDS in 27 (65.9%), gastrointestinal bleeding in 21 (51.2%), and bacteremia in 6 (35.3%) patients (<xref rid="jcm-09-01073-t004" ref-type="table">Table 4</xref>).</p></sec><sec id="sec3dot5-jcm-09-01073"><title>3.5. Comparison of Survivors and Nonsurvivors</title><p>Compared with survivors, nonsurvivors had a significantly shorter length of hospital stay. Upon hospital admission, elevation of myoglobin and creatine kinase&#x02013;MB isoenzyme levels was significantly associated with mortality. Moreover, a significantly higher white blood cell count and high creatinine, aspartate aminotransferase, C&#x02013;reactive protein, myoglobin, creatine kinase&#x02013;MB isoenzyme, and lactate concentrations, in addition to lower platelet count during the course of hospitalization, were reported in nonsurvivors. Nonsurvivors received ECMO treatment and had a significantly higher incidence of acute kidney injury, pneumothorax, ARDS, and gastrointestinal bleeding than survivors. Multivariate analysis showed that high lactate level during hospitalization (adjusted odds ratio [aOR]: 1.041; 95% confidence interval [CI]: 1.019&#x02013;1.064; <italic>p</italic> &#x0003c; 0.001), ARDS (aOR: 10.098; 95% CI: 2.505&#x02013;40.714; <italic>p</italic> = 0.001), acute kidney injury (aOR: 9.019; 95% CI: 1.804&#x02013;45.089; <italic>p</italic> = 0.007), and gastrointestinal bleeding (aOR: 3.828; 95% CI: 1.180&#x02013;12.415; <italic>p</italic> = 0.025) were independent predictors of mortality in critically ill influenza patients (<xref rid="jcm-09-01073-t005" ref-type="table">Table 5</xref>).</p></sec><sec id="sec3dot6-jcm-09-01073"><title>3.6. Event-Based Algorithm</title><p>The median highest lactate values (reference value &#x0003c;2.1 mmol/L) and median time from presentation to the highest lactate level among survivors and nonsurvivors were 2.7 mmol/L and 4.3 mmol/L and three days and four days, respectively. We selected the lactate variable in multivariate analyses and plotted the ROC curve to identify the optimal cutoff value for predicting mortality. The optimal cutoff of lactate level for predicting mortality was 3.7 mmol/L with an area under curve of 0.728, and the sensitivity and specificity of this cutoff were estimated at 63.9% and 74.1%, respectively (<xref ref-type="fig" rid="jcm-09-01073-f001">Figure 1</xref>). We then created an event-associated algorithm that included lactate level and ARDS&#x02014;the two variables that were independently and significantly associated with death in multivariate analyses (<xref ref-type="fig" rid="jcm-09-01073-f002">Figure 2</xref>). Fifteen (75.0%) of the 20 patients with lactate levels of 3.7 mmol/L or above and with ARDS died, compared with only one (7.7%) of 13 patients with lactate levels below 2.1 mmol/L and without ARDS (<italic>p</italic> &#x0003c; 0.001) and 1 (10%) of 10 patients with lactate levels between 2.1 mmol/L and 3.7 mmol/L and without ARDS (<italic>p</italic> &#x0003c; 0.001).</p></sec></sec><sec sec-type="discussion" id="sec4-jcm-09-01073"><title>4. Discussion</title><p>In a study involving 444 adult patients with influenza in hospitals in the United States, the mortality rate was 20.9% [<xref rid="B21-jcm-09-01073" ref-type="bibr">21</xref>]. Furthermore, a mortality rate of 20.6% was reported by Francisco et al. in their study of 2059 patients admitted to ICUs for influenza infection [<xref rid="B22-jcm-09-01073" ref-type="bibr">22</xref>]. In our study, a mortality rate as high as 40% was found in 102 critically ill adult patients with influenza. However, which variables can predict poor patient outcomes after influenza virus infection remain to be elucidated. In the present study, our dataset included clinical signs and symptoms and laboratory results at presentation and the entire course of hospitalization as well as complications during the clinical course. We determined which demographic, clinical, and laboratory findings were associated with death that could help clinicians deliver timely and sufficient treatment to critically ill influenza patients. Our results underscore that high blood lactate levels during hospitalization, ARDS, acute kidney injury, and gastrointestinal bleeding were independent risk factors of mortality in critically ill influenza patients.</p><p>High blood lactate levels indicate tissue hypoxia due to increased lactate generation via anaerobic glycolysis [<xref rid="B23-jcm-09-01073" ref-type="bibr">23</xref>]. High blood lactate levels have been correlated with poor outcomes in patients with bacterial sepsis and septic shock [<xref rid="B24-jcm-09-01073" ref-type="bibr">24</xref>]. In the present study, high blood lactate levels were found to be significantly and independently associated with fatal outcomes in critically ill influenza patients. In addition, nonsurvivors had a significantly higher prevalence of acute kidney injury and gastrointestinal bleeding and received ECMO treatment in our series. Importantly, acute kidney injury and gastrointestinal bleeding have been shown to be independent risk factors of mortality. We believe that these complications are caused by clinicians&#x02019; lack of awareness of early detection of organ hypoperfusion. As patients in early phases of hypoperfusion do not always show obvious clinical signs, blood lactate level may be an important marker for this disorder. Thus, timely recognition of organ hypoperfusion and initiation of effective volume replacement to reverse tissue hypoxia are critical steps in preventing mortality and morbidity. Notably, the median time interval from patient arrival to measurement of highest blood lactate was four days in nonsurvivors in our series. Further, the median time from illness onset to fatality was 18.5 days. This finding indicates that blood lactate levels can be a useful early marker assisting clinicians in predicting the outcomes in critically ill influenza patients. </p><p>Our series here showed gastrointestinal bleeding occurred in one-third of included patients and more than half of them with fatal outcome. Stress ulcer prophylaxis for critically ill patients is not universally practiced in our series. The causes of gastrointestinal bleeding in these patients are multifactorial. Our study underlines that clinicians should be alert to possible gastrointestinal bleeding when caring for a critically ill influenza patient because this complication potentially leads to death if it is not recognized early and treated accordingly.</p><p>ARDS is a lethal complication of influenza infection [<xref rid="B25-jcm-09-01073" ref-type="bibr">25</xref>]. Ortiz et al. estimated that the incidence of influenza-associated acute respiratory failure was 2.7 events per 100,000 person&#x02013;years [<xref rid="B26-jcm-09-01073" ref-type="bibr">26</xref>]. In a study of 58 patients with ARDS, 28 (48.2%) were due to influenza virus infection, and 32.1% of the patients with influenza-associated ARDS received ECMO treatment [<xref rid="B27-jcm-09-01073" ref-type="bibr">27</xref>]. Davies et al. reported that the incidence of pdm09 A/H1-associated ARDS sufficient to warrant consideration of ECMO was estimated at 2.6 cases per million population [<xref rid="B28-jcm-09-01073" ref-type="bibr">28</xref>]. ARDS is an independent risk factor for hospital mortality in critically ill influenza patients, and the mortality rate can be as high as 52% [<xref rid="B29-jcm-09-01073" ref-type="bibr">29</xref>]. The present study results are consistent with previous findings wherein 97% of critically ill influenza patients developed acute respiratory failure with a median time of four days between illness onset and respiratory failure, and 51% of them subsequently developed ARDS during their clinical course. In addition, approximately one-third of the patients with influenza-associated ARDS required ECMO for profound hypoxemic respiratory failure. Our study highlights that severe oxygenation failure occurred rapidly after hospital admission and that clinicians should not delay delivering appropriate rescue therapies as well as deploying ICU resources to meet this treatment requirement, particularly during the influenza epidemic.</p><p>In the present study, we established a simple event-associated algorithm including blood lactate level and ARDS for timely detection of critically ill influenza patients who are at greater risk of mortality. Notably, critically ill influenza patients without ARDS but with a blood lactate concentration of 3.7 mmol/L had an in-hospital mortality of 47.1%, and more importantly, the mortality rate increased to 75% for those with high blood lactate (&#x02265;3.7 mmol/L) and those that developed ARDS. In contrast, only 7.7% of critically ill influenza patients without ARDS and with normal blood lactate levels died. Considering the high mortality rate among critically ill influenza patients, this event-based algorithm could aid in the timely decision-making process and provision of prompt intensive care for patients with potentially fatal outcomes, particularly in resource-limited areas; some key laboratory tests such as blood lactate might be of greater value than others when allocating limited healthcare resources.</p><p>Previous studies have shown that early administration of an antiviral agent is associated with a shorter duration and reduced severity of illness [<xref rid="B14-jcm-09-01073" ref-type="bibr">14</xref>,<xref rid="B15-jcm-09-01073" ref-type="bibr">15</xref>,<xref rid="B16-jcm-09-01073" ref-type="bibr">16</xref>]. Greater benefits were shown with early treatment initiated within two days after the onset of illness [<xref rid="B30-jcm-09-01073" ref-type="bibr">30</xref>,<xref rid="B31-jcm-09-01073" ref-type="bibr">31</xref>,<xref rid="B32-jcm-09-01073" ref-type="bibr">32</xref>]. In our study, the median time from illness onset to hospital presentation was three days and more than two-thirds of the patients received delayed (48 h after illness onset) antiviral treatment. Although the provision of antiviral therapy between survivors and nonsurvivors did not differ significantly in our series, the importance of early treatment with antivirals in critically ill influenza patients cannot be overemphasized.</p><p>In our study, bacteremia was detected in 17 critically ill adult patients. Importantly, five of them acquired bacteremia within 48 h after hospitalization, and in three cases, the infection was caused by <italic>Staphylococcus aureus</italic>. A report of the 2009&#x02013;2010 influenza pandemic among critically ill children revealed that nearly 5% of the patients had bacteremia within 72 h and <italic>Staphylococcus aureus</italic> was the most frequently isolated bacterium, which contributed to the death rate in the current pandemic [<xref rid="B33-jcm-09-01073" ref-type="bibr">33</xref>]. In a study of 32 influenza-positive patients (including pediatric and adult patients), poor outcomes were found among patients who were coinfected with influenza viruses and <italic>Staphylococcus aureus</italic> [<xref rid="B34-jcm-09-01073" ref-type="bibr">34</xref>]. Although we were unable to conclude whether or not initiating timely additional antimicrobial treatment in critically ill influenza patients led to better clinical outcomes, our findings and previous reports underscore that <italic>Staphylococcus aureus</italic> remains the most important cause of bacterial coinfection in pediatric and adult influenza patients.</p><p>Invasive pulmonary <italic>Aspergillus</italic> as a coinfection in patients with severe influenza has been described [<xref rid="B35-jcm-09-01073" ref-type="bibr">35</xref>,<xref rid="B36-jcm-09-01073" ref-type="bibr">36</xref>,<xref rid="B37-jcm-09-01073" ref-type="bibr">37</xref>]. In a cohort study involving seven ICUs over a period of seven influenza seasons showed that influenza and the use of corticosteroids were independent risk factors for invasive aspergillosis [<xref rid="B35-jcm-09-01073" ref-type="bibr">35</xref>]. In the present study, invasive pulmonary aspergillosis was confirmed in two deceased influenza patients with high galactomannan index in bronchoalveolar lavage fluid. This finding emphasizes that clinicians should be aware of the risk of invasive aspergillosis in critically ill influenza patients, particularly immunocompromised patients or those receiving corticosteroids. Further studies are needed to understand the incidence, risk factors, and clinical features of invasive pulmonary aspergillosis in influenza patients.</p><p>In 2003, an avian influenza virus of H5N1 subtype was isolated from a smuggled duck in Kinmen Island of Taiwan [<xref rid="B38-jcm-09-01073" ref-type="bibr">38</xref>]. However, no locally acquired H5N1 disease in humans had been reported in Taiwan [<xref rid="B39-jcm-09-01073" ref-type="bibr">39</xref>]. Thus, none of the patients in this series tested positive for H5N1.</p><p>This study has several potential limitations. First, given the retrospective nature of the study, information on vaccination status, including pneumococcus and influenza, and some missing laboratory data such as pneumonia severity index and coagulation profile, were not collected. Second, the study population comprised adult patients; therefore, the results cannot be generalized to pediatric patients. However, the strengths of this study include a detailed description of clinical and laboratory information at presentation and the entire hospitalization course of critically ill patients with influenza. We highlighted the key factors associated with poor outcomes for critically ill influenza patients and established a decision-making algorithm that can take advantage of simple clinical and laboratory evaluations. </p></sec><sec sec-type="conclusions" id="sec5-jcm-09-01073"><title>5. Conclusions</title><p>We identified clinical and laboratory predictors of mortality that could aid in the prediction of the poor outcomes in hospitalized critically ill influenza patients, as timely intensive supportive care might be lifesaving. Medical services and ICUs can be overwhelmed during the peak of influenza epidemics, particularly in point-of-care resource-limited areas. Our findings could substantially assist with allocation of resources in the selection of the main key clinical data in primary care at the initial clinical evaluation of critically ill influenza patients.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank the staff members in the Intensive Care Units of Kaohsiung Chang Gung Memorial Hospital for the management of patients.</p></ack><notes><title>Author Contributions</title><p>I.-K.L. made substantial contributions to the conception, study design, data analysis and interpretation, and drafting, editing, and submitting the manuscript. J.-C.H. made substantial contributions to the data collection, data analysis, and writing the manuscript. W.-C.H., Y.-C.C., and C.-Y.T. contributed to the design of the study and interpreted the findings. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This study was supported by a grant (document no. CMRPG8H0241 to I.-K.L.) from Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-jcm-09-01073"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>K.G.</given-names></name><name><surname>Wood</surname><given-names>J.M.</given-names></name><name><surname>Zambon</surname><given-names>M.</given-names></name></person-group><article-title>Influenza</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>1733</fpage><lpage>1745</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)14854-4</pub-id><pub-id pub-id-type="pmid">14643124</pub-id></element-citation></ref><ref id="B2-jcm-09-01073"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>W.W.</given-names></name><name><surname>Shay</surname><given-names>D.K.</given-names></name><name><surname>Weintraub</surname><given-names>E.</given-names></name><name><surname>Brammer</surname><given-names>L.</given-names></name><name><surname>Bridges</surname><given-names>C.B.</given-names></name><name><surname>Cox</surname><given-names>N.J.</given-names></name><name><surname>Fukuda</surname><given-names>K.</given-names></name></person-group><article-title>Influenza-associated hospitalizations in the United States</article-title><source>JAMA</source><year>2004</year><volume>292</volume><fpage>1333</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.1001/jama.292.11.1333</pub-id><?supplied-pmid 15367555?><pub-id pub-id-type="pmid">15367555</pub-id></element-citation></ref><ref id="B3-jcm-09-01073"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention (CDC)</collab></person-group><article-title>Estimates of deaths associated with seasonal influenza&#x02014;United States, 1976&#x02013;2007</article-title><source>MMWR. Morb. Mortal. Wkly. Rep.</source><year>2010</year><volume>59</volume><fpage>1057</fpage><lpage>1062</lpage><pub-id pub-id-type="pmid">20798667</pub-id></element-citation></ref><ref id="B4-jcm-09-01073"><label>4.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization (WHO)</collab></person-group><article-title>Influenza (Seasonal)</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/influenza">https://www.who.int/news-room/fact-sheets/detail/influenza</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-01-12">(accessed on 12 January 2020)</date-in-citation></element-citation></ref><ref id="B5-jcm-09-01073"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iuliano</surname><given-names>A.D.</given-names></name><name><surname>Roguski</surname><given-names>K.M.</given-names></name><name><surname>Chang</surname><given-names>H.H.</given-names></name><name><surname>Muscatello</surname><given-names>D.J.</given-names></name><name><surname>Palekar</surname><given-names>R.</given-names></name><name><surname>Tempia</surname><given-names>S.</given-names></name><name><surname>Cohen</surname><given-names>C.</given-names></name><name><surname>Gran</surname><given-names>J.M.</given-names></name><name><surname>Schanzer</surname><given-names>D.</given-names></name><name><surname>Cowling</surname><given-names>B.J.</given-names></name><etal/></person-group><article-title>Estimates of global seasonal influenza-associated respiratory mortality: A modelling study</article-title><source>Lancet</source><year>2018</year><volume>391</volume><fpage>1285</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)33293-2</pub-id><pub-id pub-id-type="pmid">29248255</pub-id></element-citation></ref><ref id="B6-jcm-09-01073"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawood</surname><given-names>F.S.</given-names></name><name><surname>Jain</surname><given-names>S.</given-names></name><name><surname>Finelli</surname><given-names>L.</given-names></name><name><surname>Shaw</surname><given-names>M.W.</given-names></name><name><surname>Lindstrom</surname><given-names>S.</given-names></name><name><surname>Garten</surname><given-names>R.J.</given-names></name><name><surname>Gubareva</surname><given-names>L.V.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Bridges</surname><given-names>C.B.</given-names></name><name><surname>Uyeki</surname><given-names>T.M.</given-names></name></person-group><article-title>Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine origin influenza A (H1N1) virus in humans</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>360</volume><fpage>2605</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/nejmoa0903810</pub-id><pub-id pub-id-type="pmid">19423869</pub-id></element-citation></ref><ref id="B7-jcm-09-01073"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>S.S.</given-names></name><name><surname>Swerdlow</surname><given-names>D.L.</given-names></name><name><surname>Borse</surname><given-names>R.H.</given-names></name><name><surname>Prabhu</surname><given-names>V.S.</given-names></name><name><surname>Finelli</surname><given-names>L.</given-names></name><name><surname>Atkins</surname><given-names>C.Y.</given-names></name><name><surname>Owusu-Edusei</surname><given-names>K.</given-names></name><name><surname>Bell</surname><given-names>B.</given-names></name><name><surname>Mead</surname><given-names>P.S.</given-names></name><name><surname>Biggerstall</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009&#x02013;April 2010)</article-title><source>Clin. Infect. Dis.</source><year>2011</year><volume>52</volume><fpage>S75</fpage><lpage>S82</lpage><pub-id pub-id-type="doi">10.1093/cid/ciq012</pub-id><pub-id pub-id-type="pmid">21342903</pub-id></element-citation></ref><ref id="B8-jcm-09-01073"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Gu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Xue</surname><given-names>C.X.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>Risk factors for nosocomial infection among hospitalised severe influenza A(H1N1)pdm09 patients</article-title><source>Respir. Med.</source><year>2018</year><volume>134</volume><fpage>86</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2017.11.017</pub-id><pub-id pub-id-type="pmid">29413513</pub-id></element-citation></ref><ref id="B9-jcm-09-01073"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paddock</surname><given-names>C.D.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Denison</surname><given-names>A.M.</given-names></name><name><surname>Bartlett</surname><given-names>J.H.</given-names></name><name><surname>Holman</surname><given-names>R.C.</given-names></name><name><surname>Deleon-Carners</surname><given-names>M.</given-names></name><name><surname>Emery</surname><given-names>S.L.</given-names></name><name><surname>Drew</surname><given-names>C.P.</given-names></name><name><surname>Shieh</surname><given-names>W.J.</given-names></name><name><surname>Uyeki</surname><given-names>T.M.</given-names></name></person-group><article-title>Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection</article-title><source>J. Infect. Dis.</source><year>2012</year><volume>205</volume><fpage>895</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir861</pub-id><pub-id pub-id-type="pmid">22291193</pub-id></element-citation></ref><ref id="B10-jcm-09-01073"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daoud</surname><given-names>A.</given-names></name><name><surname>Laktineh</surname><given-names>A.</given-names></name><name><surname>Macrander</surname><given-names>C.</given-names></name><name><surname>Mushtaq</surname><given-names>A.</given-names></name><name><surname>Soubani</surname><given-names>A.O.</given-names></name></person-group><article-title>Pulmonary complications of influenza infection: A targeted narrative review</article-title><source>Postgrad. Med.</source><year>2019</year><volume>131</volume><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1080/00325481.2019.1592400</pub-id><pub-id pub-id-type="pmid">30845866</pub-id></element-citation></ref><ref id="B11-jcm-09-01073"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Zarychanski</surname><given-names>R.</given-names></name><name><surname>Pinto</surname><given-names>R.</given-names></name><name><surname>Cook</surname><given-names>D.J.</given-names></name><name><surname>Marshall</surname><given-names>J.</given-names></name><name><surname>Lacroix</surname><given-names>J.</given-names></name><name><surname>Stelfox</surname><given-names>T.</given-names></name><name><surname>Bagshaw</surname><given-names>S.</given-names></name><name><surname>Choong</surname><given-names>K.</given-names></name><name><surname>Lamontagne</surname><given-names>F.</given-names></name></person-group><article-title>Canadian Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza A (H1N1) infection in Canada</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>1872</fpage><lpage>1879</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.1496</pub-id><pub-id pub-id-type="pmid">19822627</pub-id></element-citation></ref><ref id="B12-jcm-09-01073"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rello</surname><given-names>J.</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>A.</given-names></name><name><surname>Iba&#x000f1;ez</surname><given-names>P.</given-names></name><name><surname>Socias</surname><given-names>L.</given-names></name><name><surname>Cebrian</surname><given-names>J.</given-names></name><name><surname>Marques</surname><given-names>A.</given-names></name><name><surname>Guerrero</surname><given-names>J.</given-names></name><name><surname>Ruiz-Santana</surname><given-names>S.</given-names></name><name><surname>Marquez</surname><given-names>E.</given-names></name><name><surname>Nogel-Saez</surname><given-names>F.D.</given-names></name></person-group><article-title>H1N1 SEMICYUC Working Group. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain</article-title><source>Crit. Care</source><year>2009</year><volume>13</volume><fpage>R148</fpage><pub-id pub-id-type="doi">10.1186/cc8044</pub-id><?supplied-pmid 19747383?><pub-id pub-id-type="pmid">19747383</pub-id></element-citation></ref><ref id="B13-jcm-09-01073"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dom&#x000ed;nguez-Cherit</surname><given-names>G.</given-names></name><name><surname>Lapinsky</surname><given-names>S.E.</given-names></name><name><surname>Macias</surname><given-names>A.E.</given-names></name><name><surname>Pinto</surname><given-names>R.</given-names></name><name><surname>Espinosa-Perez</surname><given-names>L.</given-names></name><name><surname>de la Torre</surname><given-names>A.</given-names></name><name><surname>Poblano-Morales</surname><given-names>M.</given-names></name><name><surname>Baltazar-Torres</surname><given-names>J.A.</given-names></name><name><surname>Bautista</surname><given-names>E.</given-names></name><name><surname>Martinez</surname><given-names>A.</given-names></name></person-group><article-title>Critically Ill patients with 2009 influenza A(H1N1) in Mexico</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>1880</fpage><lpage>1887</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.1536</pub-id><?supplied-pmid 19822626?><pub-id pub-id-type="pmid">19822626</pub-id></element-citation></ref><ref id="B14-jcm-09-01073"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobson</surname><given-names>J.</given-names></name><name><surname>Whitley</surname><given-names>R.J.</given-names></name><name><surname>Pocock</surname><given-names>S.</given-names></name><name><surname>Monto</surname><given-names>A.S.</given-names></name></person-group><article-title>Oseltamivir treatment for influenza in adults: A meta analysis of randomised controlled trials</article-title><source>Lancet</source><year>2015</year><volume>385</volume><fpage>1729</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)62449-1</pub-id><pub-id pub-id-type="pmid">25640810</pub-id></element-citation></ref><ref id="B15-jcm-09-01073"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doll</surname><given-names>M.K.</given-names></name><name><surname>Winters</surname><given-names>N.</given-names></name><name><surname>Boikos</surname><given-names>C.</given-names></name><name><surname>Kraicer-Melamed</surname><given-names>H.</given-names></name><name><surname>Gore</surname><given-names>G.</given-names></name><name><surname>Quach</surname><given-names>C.</given-names></name></person-group><article-title>Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: A systematic review of systematic reviews and/or meta analyses</article-title><source>J. Antimicrob. Chemother.</source><year>2017</year><volume>72</volume><fpage>2990</fpage><lpage>3007</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx271</pub-id><?supplied-pmid 28961794?><pub-id pub-id-type="pmid">28961794</pub-id></element-citation></ref><ref id="B16-jcm-09-01073"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fry</surname><given-names>A.M.</given-names></name><name><surname>Goswami</surname><given-names>D.</given-names></name><name><surname>Nahar</surname><given-names>K.</given-names></name><name><surname>Sharmin</surname><given-names>A.T.</given-names></name><name><surname>Rahman</surname><given-names>M.</given-names></name><name><surname>Gubareva</surname><given-names>L.</given-names></name><name><surname>Azim</surname><given-names>T.</given-names></name><name><surname>Bresee</surname><given-names>J.</given-names></name><name><surname>Luby</surname><given-names>S.P.</given-names></name><name><surname>Brooks</surname><given-names>W.A.</given-names></name></person-group><article-title>Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: A randomised placebo-controlled trial</article-title><source>Lancet Infect. Dis.</source><year>2014</year><volume>14</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(13)70267-6</pub-id><pub-id pub-id-type="pmid">24268590</pub-id></element-citation></ref><ref id="B17-jcm-09-01073"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ARDS Definition Task Force</collab><name><surname>Ranieri</surname><given-names>V.M.</given-names></name><name><surname>Rubenfeld</surname><given-names>G.D.</given-names></name><name><surname>Thompson</surname><given-names>B.T.</given-names></name><name><surname>Ferguson</surname><given-names>N.D.</given-names></name><name><surname>Caldwell</surname><given-names>E.</given-names></name><name><surname>Fan</surname><given-names>E.</given-names></name><name><surname>Camporota</surname><given-names>L.</given-names></name><name><surname>Slutsky</surname><given-names>A.S.</given-names></name></person-group><article-title>Acute Respiratory Distress Syndrome</article-title><source>JAMA</source><year>2012</year><volume>307</volume><fpage>2526</fpage><lpage>2533</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.5669</pub-id><pub-id pub-id-type="pmid">22797452</pub-id></element-citation></ref><ref id="B18-jcm-09-01073"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>I.</given-names></name><name><surname>Budka</surname><given-names>H.</given-names></name><name><surname>Chaudhuri</surname><given-names>A.</given-names></name><name><surname>Koskiniemi</surname><given-names>M.</given-names></name><name><surname>Sainio</surname><given-names>K.</given-names></name><name><surname>Salonen</surname><given-names>O.</given-names></name><name><surname>Kennedy</surname><given-names>P.G.</given-names></name></person-group><article-title>Viral meningoencephalitis: A review of diagnostic methods and guidelines for management</article-title><source>Eur. J. Neurol.</source><year>2010</year><volume>17</volume><fpage>e57</fpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2010.02970.x</pub-id></element-citation></ref><ref id="B19-jcm-09-01073"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heer</surname><given-names>K.D.</given-names></name><name><surname>Gerritsen</surname><given-names>M.G.</given-names></name><name><surname>Visser</surname><given-names>C.E.</given-names></name><name><surname>Leeflang</surname><given-names>M.M.</given-names></name></person-group><article-title>Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients</article-title><source>Cochrane Database Syst. Rev.</source><year>2019</year><pub-id pub-id-type="doi">10.1002/14651858.cd012399.pub2</pub-id></element-citation></ref><ref id="B20-jcm-09-01073"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maertens</surname><given-names>J.</given-names></name><name><surname>Theunissen</surname><given-names>K.</given-names></name><name><surname>Verbeken</surname><given-names>E.</given-names></name><name><surname>Lagrou</surname><given-names>K.</given-names></name><name><surname>Verhaegen</surname><given-names>J.</given-names></name><name><surname>Boogaerts</surname><given-names>M.</given-names></name><name><surname>Eldere</surname><given-names>J.V.</given-names></name></person-group><article-title>Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients</article-title><source>Br. J. Haematol.</source><year>2004</year><volume>126</volume><fpage>852</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2004.05140.x</pub-id><pub-id pub-id-type="pmid">15352990</pub-id></element-citation></ref><ref id="B21-jcm-09-01073"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>N.S.</given-names></name><name><surname>Greenberg</surname><given-names>J.A.</given-names></name><name><surname>McNulty</surname><given-names>M.C.</given-names></name><name><surname>Gregg</surname><given-names>K.S.</given-names></name><name><surname>Riddell</surname><given-names>J.</given-names></name><name><surname>Mangino</surname><given-names>J.E.</given-names></name><name><surname>Weber</surname><given-names>D.M.</given-names></name><name><surname>Hebert</surname><given-names>C.L.</given-names></name><name><surname>Marzec</surname><given-names>N.S.</given-names></name><name><surname>Barron</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Severe Influenza in 33 US Hospitals, 2013&#x02013;2014: Complications and Risk Factors for Death in 507 Patients</article-title><source>Infect. Control Hosp. Epidemiol.</source><year>2015</year><volume>36</volume><fpage>1251</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1017/ice.2015.170</pub-id><pub-id pub-id-type="pmid">26224364</pub-id></element-citation></ref><ref id="B22-jcm-09-01073"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000c1;lvarez-Lerma</surname><given-names>F.</given-names></name><name><surname>Mar&#x000ed;n-Corral</surname><given-names>J.</given-names></name><name><surname>Vila</surname><given-names>C.</given-names></name><name><surname>Masclans</surname><given-names>J.R.</given-names></name><name><surname>Gonz&#x000e1;lez de Molina</surname><given-names>F.J.</given-names></name><name><surname>Mart&#x000ed;n Loeches</surname><given-names>I.</given-names></name><name><surname>Barbadillo</surname><given-names>S.</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>A.</given-names></name></person-group><article-title>H1N1 GETGAG/SEMICYUC Study Group. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome</article-title><source>Crit. Care</source><year>2016</year><volume>20</volume><pub-id pub-id-type="doi">10.1186/s13054-016-1512-1</pub-id></element-citation></ref><ref id="B23-jcm-09-01073"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fall</surname><given-names>P.J.</given-names></name><name><surname>Szerlip</surname><given-names>H.M.</given-names></name></person-group><article-title>Lactic Acidosis: From Sour Milk to Septic Shock</article-title><source>J. Intensive Care Med.</source><year>2005</year><volume>20</volume><fpage>255</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1177/0885066605278644</pub-id><pub-id pub-id-type="pmid">16145217</pub-id></element-citation></ref><ref id="B24-jcm-09-01073"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikkelsen</surname><given-names>M.E.</given-names></name><name><surname>Miltiades</surname><given-names>A.N.</given-names></name><name><surname>Gaieski</surname><given-names>D.F.</given-names></name><name><surname>Goyal</surname><given-names>M.</given-names></name><name><surname>Fuchs</surname><given-names>B.D.</given-names></name><name><surname>Shah</surname><given-names>C.V.</given-names></name><name><surname>Bellamy</surname><given-names>S.L.</given-names></name><name><surname>Christie</surname><given-names>J.D.</given-names></name></person-group><article-title>Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock</article-title><source>Crit. Care Med.</source><year>2009</year><volume>37</volume><fpage>1670</fpage><lpage>1677</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e31819fcf68</pub-id><?supplied-pmid 19325467?><pub-id pub-id-type="pmid">19325467</pub-id></element-citation></ref><ref id="B25-jcm-09-01073"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Short</surname><given-names>K.R.</given-names></name><name><surname>Kroeze</surname><given-names>E.</given-names></name><name><surname>Fouchier</surname><given-names>R.</given-names></name><name><surname>Kuiken</surname><given-names>T.</given-names></name></person-group><article-title>Pathogenesis of influenza-induced acute respiratory distress syndrome</article-title><source>Lancet Infect. Dis.</source><year>2014</year><volume>14</volume><fpage>57</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(13)70286-X</pub-id><pub-id pub-id-type="pmid">24239327</pub-id></element-citation></ref><ref id="B26-jcm-09-01073"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz</surname><given-names>J.R.</given-names></name><name><surname>Neuzil</surname><given-names>K.M.</given-names></name><name><surname>Rue</surname><given-names>T.C.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Shay</surname><given-names>D.K.</given-names></name><name><surname>Cheng</surname><given-names>P.Y.</given-names></name><name><surname>Cooke</surname><given-names>C.R.</given-names></name><name><surname>Goss</surname><given-names>C.H.</given-names></name></person-group><article-title>Population-based Incidence Estimates of Influenza-associated Respiratory Failure Hospitalizations, 2003 to 2009</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2013</year><volume>188</volume><fpage>710</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1164/rccm.201212-2341OC</pub-id><pub-id pub-id-type="pmid">23855650</pub-id></element-citation></ref><ref id="B27-jcm-09-01073"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>J.W.</given-names></name><name><surname>Ju</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>S.J.</given-names></name><name><surname>Cho</surname><given-names>M.C.</given-names></name><name><surname>Cho</surname><given-names>Y.J.</given-names></name><name><surname>Jeong</surname><given-names>Y.Y.</given-names></name><name><surname>Lee</surname><given-names>J.D.</given-names></name><name><surname>Kim</surname><given-names>H.C.</given-names></name></person-group><article-title>Characteristics and Outcomes of Patients with Pulmonary Acute Respiratory Distress Syndrome Infected with Influenza versus Other Respiratory Viruses</article-title><source>Tuberc. Respir. Dis.</source><year>2019</year><volume>82</volume><fpage>328</fpage><pub-id pub-id-type="doi">10.4046/trd.2019.0017</pub-id></element-citation></ref><ref id="B28-jcm-09-01073"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>A.</given-names></name><name><surname>Jones</surname><given-names>D.</given-names></name><name><surname>Bailey</surname><given-names>M.</given-names></name><name><surname>Beca</surname><given-names>J.</given-names></name><name><surname>Bellomo</surname><given-names>R.</given-names></name><name><surname>Blackwell</surname><given-names>N.</given-names></name><name><surname>Forrest</surname><given-names>P.</given-names></name><name><surname>Gattas</surname><given-names>D.</given-names></name><name><surname>Granger</surname><given-names>E.</given-names></name></person-group><article-title>Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>1888</fpage><lpage>1895</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.1535</pub-id><pub-id pub-id-type="pmid">19822628</pub-id></element-citation></ref><ref id="B29-jcm-09-01073"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Yilmaz</surname><given-names>M.</given-names></name><name><surname>Kojicic</surname><given-names>M.</given-names></name><name><surname>Fern&#x000e1;ndez-P&#x000e9;rez</surname><given-names>E.</given-names></name><name><surname>Wahab</surname><given-names>R.</given-names></name><name><surname>Huskins</surname><given-names>W.C.</given-names></name><name><surname>Afessa</surname><given-names>B.</given-names></name><name><surname>Truwit</surname><given-names>J.D.</given-names></name><name><surname>Gajic</surname><given-names>O.</given-names></name></person-group><article-title>Outcome of critically ill patients with influenza virus infection</article-title><source>J. Clin. Virol.</source><year>2009</year><volume>46</volume><fpage>275</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2009.07.015</pub-id><pub-id pub-id-type="pmid">19699141</pub-id></element-citation></ref><ref id="B30-jcm-09-01073"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>S.</given-names></name><name><surname>Kamimoto</surname><given-names>L.</given-names></name><name><surname>Bramley</surname><given-names>A.M.</given-names></name><name><surname>Schmitz</surname><given-names>A.M.</given-names></name><name><surname>Benoit</surname><given-names>S.R.</given-names></name><name><surname>Louie</surname><given-names>J.</given-names></name><name><surname>Sugerman</surname><given-names>D.E.</given-names></name><name><surname>Druckenmiller</surname><given-names>J.K.</given-names></name><name><surname>Ritger</surname><given-names>K.A.</given-names></name><name><surname>Chugh</surname><given-names>R.</given-names></name></person-group><article-title>Hospitalized Patients with 2009 H1N1 Influenza in the United States, April&#x02013;June 2009</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>361</volume><fpage>1935</fpage><lpage>1944</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0906695</pub-id><pub-id pub-id-type="pmid">19815859</pub-id></element-citation></ref><ref id="B31-jcm-09-01073"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanshaoworakul</surname><given-names>W.</given-names></name><name><surname>Simmerman</surname><given-names>J.M.</given-names></name><name><surname>Narueponjirakul</surname><given-names>U.</given-names></name><name><surname>Sanasuttipun</surname><given-names>W.</given-names></name><name><surname>Shinde</surname><given-names>V.</given-names></name><name><surname>Kaewchana</surname><given-names>S.</given-names></name><name><surname>Areechokechai</surname><given-names>D.</given-names></name><name><surname>Levy</surname><given-names>J.</given-names></name><name><surname>Ungchusak</surname><given-names>K.</given-names></name></person-group><article-title>Severe Human Influenza Infections in Thailand: Oseltamivir Treatment and Risk Factors for Fatal Outcome</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0006051</pub-id></element-citation></ref><ref id="B32-jcm-09-01073"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A.</given-names></name></person-group><article-title>Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): Speed is life</article-title><source>J. Antimicrob. Chemother.</source><year>2011</year><volume>66</volume><fpage>959</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1093/jac/dkr090</pub-id><?supplied-pmid 21406435?><pub-id pub-id-type="pmid">21406435</pub-id></element-citation></ref><ref id="B33-jcm-09-01073"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randolph</surname><given-names>A.G.</given-names></name><name><surname>Vaughn</surname><given-names>F.</given-names></name><name><surname>Sullivan</surname><given-names>R.</given-names></name><name><surname>Rubinson</surname><given-names>L.</given-names></name><name><surname>Thompson</surname><given-names>B.T.</given-names></name><name><surname>Yoon</surname><given-names>G.</given-names></name><name><surname>Smoot</surname><given-names>E.</given-names></name><name><surname>Rice</surname><given-names>T.W.</given-names></name><name><surname>Loftis</surname><given-names>L.L.</given-names></name><name><surname>Helfaer</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Critically ill children during the 2009&#x02013;2010 influenza pandemic in the United States</article-title><source>Pediatrics</source><year>2011</year><volume>128</volume><fpage>e1450</fpage><lpage>e1458</lpage><pub-id pub-id-type="doi">10.1542/peds.2011-0774</pub-id><?supplied-pmid 22065262?><pub-id pub-id-type="pmid">22065262</pub-id></element-citation></ref><ref id="B34-jcm-09-01073"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDanel</surname><given-names>J.S.</given-names></name><name><surname>Perencevich</surname><given-names>E.N.</given-names></name><name><surname>Storm</surname><given-names>J.</given-names></name><name><surname>Diekema</surname><given-names>D.J.</given-names></name><name><surname>Herwaldt</surname><given-names>L.</given-names></name><name><surname>Johnson</surname><given-names>J.K.</given-names></name><name><surname>Winokur</surname><given-names>P.L.</given-names></name><name><surname>Schweizer</surname><given-names>M.L.</given-names></name></person-group><article-title>Increased Mortality Rates Associated withStaphylococcus aureusand Influenza Co-infection, Maryland and Iowa, USA</article-title><source>Emerg. Infect. Dis.</source><year>2016</year><volume>22</volume><fpage>1253</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.3201/eid2207.151319</pub-id><?supplied-pmid 27315549?><pub-id pub-id-type="pmid">27315549</pub-id></element-citation></ref><ref id="B35-jcm-09-01073"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schauwvlieghe</surname><given-names>A.</given-names></name><name><surname>Rijnders</surname><given-names>B.</given-names></name><name><surname>Philips</surname><given-names>N.</given-names></name><name><surname>Verwijs</surname><given-names>R.</given-names></name><name><surname>Vanderbeke</surname><given-names>L.</given-names></name><name><surname>Van Tienen</surname><given-names>C.</given-names></name><name><surname>Lagrou</surname><given-names>K.</given-names></name><name><surname>Verweij</surname><given-names>P.E.</given-names></name><name><surname>Van de Veerdonk</surname><given-names>F.L.</given-names></name><name><surname>Gommers</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study</article-title><source>Lancet Respir. Med.</source><year>2018</year><volume>6</volume><fpage>782</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(18)30274-1</pub-id><pub-id pub-id-type="pmid">30076119</pub-id></element-citation></ref><ref id="B36-jcm-09-01073"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wauters</surname><given-names>J.</given-names></name><name><surname>Baar</surname><given-names>I.</given-names></name><name><surname>Meersseman</surname><given-names>P.</given-names></name><name><surname>Meersseman</surname><given-names>W.</given-names></name><name><surname>Dams</surname><given-names>K.</given-names></name><name><surname>De Paep</surname><given-names>R.</given-names></name><name><surname>Lagrou</surname><given-names>K.</given-names></name><name><surname>Wilmer</surname><given-names>A.</given-names></name><name><surname>Jorens</surname><given-names>P.</given-names></name><name><surname>Hermans</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: A retrospective study</article-title><source>Intensive Care Med.</source><year>2012</year><volume>38</volume><fpage>1761</fpage><lpage>1768</lpage><pub-id pub-id-type="doi">10.1007/s00134-012-2673-2</pub-id><?supplied-pmid 22895826?><pub-id pub-id-type="pmid">22895826</pub-id></element-citation></ref><ref id="B37-jcm-09-01073"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van de Veerdonk</surname><given-names>F.L.</given-names></name><name><surname>Kolwijck</surname><given-names>E.</given-names></name><name><surname>Lestrade</surname><given-names>P.P.</given-names></name><name><surname>Hodiamont</surname><given-names>C.J.</given-names></name><name><surname>Rijnders</surname><given-names>B.J.</given-names></name><name><surname>van Paassen</surname><given-names>J.</given-names></name><name><surname>Haas</surname><given-names>P.J.</given-names></name><name><surname>Dos Santos</surname><given-names>C.O.</given-names></name><name><surname>Kampinga</surname><given-names>G.A.</given-names></name><name><surname>Bergmans</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>Influenza-associated Aspergillosis in Critically Ill Patients</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2017</year><volume>196</volume><fpage>524</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1164/rccm.201612-2540LE</pub-id><pub-id pub-id-type="pmid">28387526</pub-id></element-citation></ref><ref id="B38-jcm-09-01073"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M.S.</given-names></name><name><surname>Deng</surname><given-names>M.C.</given-names></name><name><surname>Lin</surname><given-names>Y.J.</given-names></name><name><surname>Chang</surname><given-names>C.Y.</given-names></name><name><surname>Shieh</surname><given-names>H.K.</given-names></name><name><surname>Shiau</surname><given-names>J.Z.</given-names></name><name><surname>Huang</surname><given-names>C.C.</given-names></name></person-group><article-title>Characterization of an H5N1 avian influenza virus from Taiwan</article-title><source>Vet. Microbiol.</source><year>2007</year><volume>124</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2007.04.021</pub-id><pub-id pub-id-type="pmid">17512143</pub-id></element-citation></ref><ref id="B39-jcm-09-01073"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>Y.N.</given-names></name><name><surname>Kuo</surname><given-names>R.L.</given-names></name><name><surname>Chen</surname><given-names>G.W.</given-names></name><name><surname>Shih</surname><given-names>S.R.</given-names></name></person-group><article-title>Centennial review of influenza in Taiwan</article-title><source>Biomed. J.</source><year>2018</year><volume>41</volume><fpage>234</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/j.bj.2018.08.002</pub-id><pub-id pub-id-type="pmid">30348266</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="jcm-09-01073-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Receiver operating characteristic curve of lactate for prediction of mortality.</p></caption><graphic xlink:href="jcm-09-01073-g001"/></fig><fig id="jcm-09-01073-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Event-based algorithm.</p></caption><graphic xlink:href="jcm-09-01073-g002"/></fig><table-wrap id="jcm-09-01073-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">jcm-09-01073-t001_Table 1</object-id><label>Table 1</label><caption><p>Characteristics and diagnostic methods of patients with severe influenza.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Overall (<italic>n</italic> = 102)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Survivors (<italic>n</italic> = 61)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nonsurvivors (<italic>n</italic> = 41)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Demographic and Clinical Features</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age, years, median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">62 (24&#x02013;93)</td><td align="center" valign="middle" rowspan="1" colspan="1">65 (24&#x02013;92)</td><td align="center" valign="middle" rowspan="1" colspan="1">61 (24&#x02013;93)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.186</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age group, <italic>N</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.068</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20&#x02013;49 year </td><td align="center" valign="middle" rowspan="1" colspan="1">20 (19.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (18)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (22)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">50&#x02013;64</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (37.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (31.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (46.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265;65 year</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (43.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">31 (50.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (31.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female gender, <italic>N</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (39)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (37.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (41.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.836</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Body mass index, median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">23.25 (16.7&#x02013;37.8) (<italic>n</italic> = 86)</td><td align="center" valign="middle" rowspan="1" colspan="1">23.8 (16.7&#x02013;35.7) (<italic>n</italic> = 55)</td><td align="center" valign="middle" rowspan="1" colspan="1">22.7 (17.8&#x02013;37.8) (<italic>n</italic> = 31)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.583</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Underlying condition, <italic>N</italic> (%)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bronchial asthma</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (6.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (6.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (7.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="middle" rowspan="1" colspan="1">56 (54.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (62.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (43.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.073</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type 2 diabetes mellitus</td><td align="center" valign="middle" rowspan="1" colspan="1">45 (44.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (45.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (41.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.689</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chronic kidney disease</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (15.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (21.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (7.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.094</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">End stage renal disease</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (8.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (8.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (9.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (7.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (11.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.139</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Liver cirrhosis </td><td align="center" valign="middle" rowspan="1" colspan="1">6 (5.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (4.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (7.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.682</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">qSOFA, median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0&#x02013;3) (<italic>n</italic> = 99)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0&#x02013;3) (<italic>n</italic> = 60)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0&#x02013;2) (<italic>n</italic> = 39)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.906</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SOFA, median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (2&#x02013;16) (<italic>n</italic> = 59)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (2&#x02013;16) (<italic>n</italic> = 34)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (3&#x02013;14) (<italic>n</italic> = 25)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.263</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Times from illness onset to hospital presentation, days, median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1&#x02013;14)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (1&#x02013;10)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1&#x02013;14)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.414</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Times from illness onset to fatality, day, median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">18.5 (2&#x02013;53)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hospital length of stay, days, median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (1&#x02013;107) </td><td align="center" valign="middle" rowspan="1" colspan="1">32 (2&#x02013;107) </td><td align="center" valign="middle" rowspan="1" colspan="1">14 (1&#x02013;53) </td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Stay in intensive care unit, <italic>N</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">98 (96.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">60 (98.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (92.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.177</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Use antibiotic at presentation, <italic>N</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">100 (98) </td><td align="center" valign="middle" rowspan="1" colspan="1">60 (98.4) </td><td align="center" valign="middle" rowspan="1" colspan="1">40 (97.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Use oseltamivir, <italic>N</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">94 (92.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">56 (91.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (92.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Use oseltamivir &#x02265;48 h after onset of illness, N/total <italic>N</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">68/94 (72.3) </td><td align="center" valign="middle" rowspan="1" colspan="1">39/56 (69.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">29/38 (76.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.639</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Use peramivir, <italic>N</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (9.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (13.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (4.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.793</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Use peramivir &#x02265;48 h after onset of illness, <italic>N</italic>/total <italic>N</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6/10 (60)</td><td align="center" valign="middle" rowspan="1" colspan="1">5/8 (62.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2 (50)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Use statin, <italic>N</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (20.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (23)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (17.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.610</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Use metformin, <italic>N</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (16.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (21.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (9.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.177</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Use vasopressor</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (43.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (24.6)</td><td align="center" valign="middle" rowspan="1" colspan="1"> 29 (70.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Diagnostic methods for influenza, <italic>N</italic>/total <italic>N</italic> (%)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Positive of influenza rapid test</td><td align="center" valign="middle" rowspan="1" colspan="1">51/93 (54.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">34/56 (60.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">17/37 (45.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Positive of RT-PCR for influenza</td><td align="center" valign="middle" rowspan="1" colspan="1">94/98 (95.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">59/61 (96.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">35/37 (94.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Positive of throat influenza viral culture </td><td align="center" valign="middle" rowspan="1" colspan="1">37/95 (38.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">23/59 (39)</td><td align="center" valign="middle" rowspan="1" colspan="1">14/36 (38.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Influenza virus subtype, <italic>N</italic> (%)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Influenza A</td><td align="center" valign="middle" rowspan="1" colspan="1">77 (75.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (72.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">33 (80.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.360</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">pdm 09 H1N1</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (33.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (37.7) </td><td align="center" valign="middle" rowspan="1" colspan="1">11 (26.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.290</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">H3N2</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (7.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (11.4) </td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.4) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.139</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Untypable A</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (28.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (21.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (39)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.073</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Influenza B</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (23.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (26.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (19.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.483</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Concurrent influenza A <sup>a</sup> and B </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;0.99</td></tr></tbody></table><table-wrap-foot><fn><p>RT-PCR, Reverse transcription-polymerase chain reaction; qSOFA, quick Sequential Organ Failure Assessment. <sup>a</sup> Untypable influenza A.</p></fn></table-wrap-foot></table-wrap><table-wrap id="jcm-09-01073-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">jcm-09-01073-t002_Table 2</object-id><label>Table 2</label><caption><p>Symptom/signs of patients with severe influenza.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Symptom/Sign at Presentation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Overall (<italic>n</italic> = 102)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Survivors (<italic>n</italic> = 61)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nonsurvivors (<italic>n</italic> = 41)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fever</td><td align="center" valign="middle" rowspan="1" colspan="1">81 (79.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">48 (78.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">33 (80.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rhinorrhea</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (7.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (4.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (12.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.262</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cough</td><td align="center" valign="middle" rowspan="1" colspan="1">85 (83.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">49 (80.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">35 (85.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.602</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sore throat</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (7.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (8.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (7.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Malaise</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (23.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (27.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (17.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.241</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Muscle pain</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (16.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (16.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (7.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.233</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Headache</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (4.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (3.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (7.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.389</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vomiting/nausea</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (5.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (8.2) </td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.397</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Diarrhea</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Abdominal pain</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chest pain</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (7.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (8.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (7.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Skin rash</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Altered consciousness</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (15.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (18.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (12.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.581</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Seizure</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (2.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (3.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dyspnea</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87 (85.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51 (83.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36 (87.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.776</td></tr></tbody></table><table-wrap-foot><fn><p>Data expressed as number (%).</p></fn></table-wrap-foot></table-wrap><table-wrap id="jcm-09-01073-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">jcm-09-01073-t003_Table 3</object-id><label>Table 3</label><caption><p>Laboratory characteristics of patients with severe influenza.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Overall (<italic>n</italic> = 102)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Survivors (<italic>n</italic> = 61)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Non&#x02013;survivors (<italic>n</italic> = 41)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold> Laboratory Data at Presentation</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">WBC, (&#x000d7;10<sup>9</sup>/L), median (range) </td><td align="center" valign="middle" rowspan="1" colspan="1">7.9 (0.5&#x02013;178)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.7 (2.1&#x02013;27.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (0.5&#x02013;178) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.921</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Platelet count, (&#x000d7;10<sup>9</sup>/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">156.5 (4&#x02013;641)</td><td align="center" valign="middle" rowspan="1" colspan="1">156 (60&#x02013;641)</td><td align="center" valign="middle" rowspan="1" colspan="1">158 (4&#x02013;365) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.407</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hemoglobin, (g/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">123 (72&#x02013;180)</td><td align="center" valign="middle" rowspan="1" colspan="1">123 (75&#x02013;180)</td><td align="center" valign="middle" rowspan="1" colspan="1">123 (72&#x02013;165)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.309</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Proportion of hematocrit, median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.36 (0.21&#x02013;0.51)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.37 (0.23&#x02013;0.51)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.36 (0.21&#x02013;0.5) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.785</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BUN, (mmol/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.7 (2.1&#x02013;39.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.9 (2.1&#x02013;39.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.5 (2.1&#x02013;35.3) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.521</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Creatinine, (&#x000b5;mol/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">88.4 (43.3&#x02013;1502.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">114.9 (44.2&#x02013;1502.8) </td><td align="center" valign="middle" rowspan="1" colspan="1">114.9 (53&#x02013;1105) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.771</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AST, (&#x000b5;kat/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2&#x02013;65.5) (<italic>n</italic> = 98)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 (0.2&#x02013;40.2) (<italic>n</italic> = 59)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1 (0.2&#x02013;65.5) (<italic>n</italic> = 39)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.619</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ALT, (&#x000b5;kat/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5 (0.1&#x02013;50) (<italic>n</italic> = 96)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5 (0.1&#x02013;50) (<italic>n</italic> = 60)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6 (0.1&#x02013;15.3) (<italic>n</italic> = 36)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.691</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CRP, (mg/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">127 (0.4&#x02013;1377) (<italic>n</italic> = 100)</td><td align="center" valign="middle" rowspan="1" colspan="1">71.4 (0.4&#x02013;380) (<italic>n</italic> = 59)</td><td align="center" valign="middle" rowspan="1" colspan="1">155.1 (1.3&#x02013;1377) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.079</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Creatine kinase, (&#x000b5;kat/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.4 (0.2&#x02013;248.5) (<italic>n</italic> = 35)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.7 (0.2&#x02013;198.5) (<italic>n</italic> = 20)</td><td align="center" valign="middle" rowspan="1" colspan="1">290 (4.9&#x02013;248.5) (<italic>n</italic> = 15)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.542</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LDH, (&#x000b5;kat/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.4 (2.9&#x02013;149.4) (<italic>n</italic> = 28)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.7 (2.9&#x02013;149.4) (<italic>n</italic> = 16)</td><td align="center" valign="middle" rowspan="1" colspan="1">11.2 (4.8&#x02013;94.6) (<italic>n</italic> = 12)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.174</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Myoglobin, (nmol/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.7 (0.003&#x02013;289.5) (<italic>n</italic> = 37)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (0.003&#x02013;289.5) (<italic>n</italic> = 19)</td><td align="center" valign="middle" rowspan="1" colspan="1">26.3 (5&#x02013;252.4) (<italic>n</italic> = 18)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.010</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Troponin&#x02013;I, (&#x000b5;g/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06 (0.01&#x02013;80) (<italic>n</italic> = 95)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06 (0.01&#x02013;15.9) (<italic>n</italic> = 56)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.05 (0.01&#x02013;80) (<italic>n</italic> = 39)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.447</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CK&#x02013;MB, (&#x000b5;kat/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06 (0.006&#x02013;5.12) (<italic>n</italic> = 84)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9 (0.05&#x02013;1.2) (<italic>n</italic> = 49)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1 (0.01&#x02013;5.1) (<italic>n</italic> = 35)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.013</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lactate, (mmol/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8 (0.7&#x02013;21.1) (<italic>n</italic> = 90)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.7 (0.9&#x02013;14.9) (<italic>n</italic> = 54)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 (0.7&#x02013;21.1) (<italic>n</italic> = 36)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.840</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Laboratory Data during Hospitalization</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Highest WBC, (&#x000d7;10<sup>9</sup>/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">16.8 (1.9&#x02013;187.6) </td><td align="center" valign="middle" rowspan="1" colspan="1">15.8 (5.2&#x02013;36.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">19.6 (1.9&#x02013;187.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nadir platelet count, (&#x000d7;10<sup>9</sup>/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">101.5 (4&#x02013;311) </td><td align="center" valign="middle" rowspan="1" colspan="1">113 (16&#x02013;311)</td><td align="center" valign="middle" rowspan="1" colspan="1">68 (4&#x02013;271)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Highest BUN, (mmol/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">19.8 (2.1&#x02013;94) </td><td align="center" valign="middle" rowspan="1" colspan="1">14.6 (3.9&#x02013;94)</td><td align="center" valign="middle" rowspan="1" colspan="1">25.3 (2.1&#x02013;80.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.055</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Highest creatinine, (&#x000b5;mol/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">183 (0.58&#x02013;44.2) </td><td align="center" valign="middle" rowspan="1" colspan="1">122 (45.7&#x02013;1418.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">289.7 (45.7&#x02013;930.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.016</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Highest AST, (&#x000b5;kat/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8 (0.3&#x02013;258.8) (<italic>n</italic> = 98)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6 (0.3&#x02013;249) (<italic>n</italic> = 59)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.6 (0.3&#x02013;258.8) (<italic>n</italic> = 39)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.033</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Highest ALT, (&#x000b5;kat/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5 (0.2&#x02013;78.2) (<italic>n</italic> = 96)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5 (0.2&#x02013;78.2) (<italic>n</italic> = 60)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6 (0.3&#x02013;65.9) (<italic>n</italic> = 36)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.226</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Highest CRP, (mg/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">213.6 (2&#x02013;2641) (<italic>n</italic> = 100)</td><td align="center" valign="middle" rowspan="1" colspan="1">186 (2&#x02013;423.3) (<italic>n</italic> = 59)</td><td align="center" valign="middle" rowspan="1" colspan="1">258.6 (5.97&#x02013;2641) (<italic>n</italic> = 41)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.019</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Highest creatine kinase, (&#x000b5;kat/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5 (0.2&#x02013;248.5) (<italic>n</italic> = 35)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5 (0.2&#x02013;199) (<italic>n</italic> = 20)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.0 (0.7&#x02013;248.5) (<italic>n</italic> = 15)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.657</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Highest LDH, (&#x000b5;kat/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">9.8 (3&#x02013;149.4) (<italic>n</italic> = 28)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.7 (2.9&#x02013;149.4) (<italic>n</italic> = 16)</td><td align="center" valign="middle" rowspan="1" colspan="1">17.5 (4.8&#x02013;9.5) (<italic>n</italic> = 12)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.059</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Highest myoglobin, (nmol/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">30.3 (0.003&#x02013;8438.8) (<italic>n</italic> = 37)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.1 (0.003&#x02013;396.1) (<italic>n</italic> = 19)</td><td align="center" valign="middle" rowspan="1" colspan="1">86.5 (5.5&#x02013;8434.8) (<italic>n</italic> = 18)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Highest Troponin I, (&#x000b5;g/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2 (0.01&#x02013;80) (<italic>n</italic> = 95)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1 (0.01&#x02013;45.6) (<italic>n</italic> = 56)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2 (0.01&#x02013;80) (<italic>n</italic> = 39)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.736</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Highest CK-MB, (&#x000b5;kat/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.09 (0.006&#x02013;13.4) (<italic>n</italic> = 84)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07 (0.006&#x02013;2.3) (<italic>n</italic> = 49)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2 (0.003&#x02013;13.4) (<italic>n</italic> = 35)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Highest lactate, (mmol/L), median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.1 (0.9&#x02013;22.5) (<italic>n</italic> = 90)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.7 (0.9&#x02013;15) (<italic>n</italic> = 54)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.3 (1.0&#x02013;22.5) (<italic>n</italic> = 36)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">The time interval from presentation to measurement of highest lactate, day, median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (1&#x02013;51) (<italic>n</italic> = 90)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1&#x02013;51) (<italic>n</italic> = 54)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (1&#x02013;30) (<italic>n</italic> = 36)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.606</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Positive of BAL galactomannan test, <italic>N</italic>/total <italic>N</italic> (%) (reference &#x0003e;0.5 index)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/6 (33.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/5 (40) </td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Positive of serum galactomannan test, <italic>N</italic>/total <italic>N</italic> (%) (reference &#x0003e;0.5 index)</td><td align="center" valign="middle" rowspan="1" colspan="1">5/23 (21.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">2/11 (18.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">3/12 (25)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Positive of urine legionella Ag, <italic>N</italic>/total <italic>N</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0/60</td><td align="center" valign="middle" rowspan="1" colspan="1">0/36</td><td align="center" valign="middle" rowspan="1" colspan="1">0/24</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive of urine streptococcus Ag, <italic>N</italic>/total <italic>N</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/41 (7.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/25 (12)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/16 (0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.268</td></tr></tbody></table><table-wrap-foot><fn><p>ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; Ag, Antigen; BAL, Bronchial alveolar lavage; BUN, blood urea nitrogen; CRP, C&#x02013;reactive protein; CK-MB, Creatine kinase-MB isoenzyme; LDH, Lactate dehydrogenase; WBC, White blood cell.</p></fn></table-wrap-foot></table-wrap><table-wrap id="jcm-09-01073-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">jcm-09-01073-t004_Table 4</object-id><label>Table 4</label><caption><p>In-hospital complications of patients with severe influenza.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Overall (<italic>n</italic> = 102)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Survivors (<italic>n</italic> = 61)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nonsurvivors (<italic>n</italic> = 41)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Acute respiratory failure</td><td align="center" valign="middle" rowspan="1" colspan="1">99 (97)</td><td align="center" valign="middle" rowspan="1" colspan="1">58 (95.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Time from onset illness to respiratory failure, day, median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (1&#x02013;27) (<italic>n</italic> = 99)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.5 (1&#x02013;16) (<italic>n</italic> = 58)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (1&#x02013;27) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.451</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Time from hospital presentation to respiratory failure, day, median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1&#x02013;21) (<italic>n</italic> = 99)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1&#x02013;13) (<italic>n</italic> = 58)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1&#x02013;21) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.921</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Use of invasive mechanical ventilator </td><td align="center" valign="middle" rowspan="1" colspan="1">90 (88.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">52 (85.2) </td><td align="center" valign="middle" rowspan="1" colspan="1">38 (92.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.352</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Duration of invasive mechanical ventilation, day, median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (1&#x02013;60) (<italic>n</italic> = 90)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (3&#x02013;60) (<italic>n</italic> = 52)</td><td align="center" valign="middle" rowspan="1" colspan="1">9.5 (1&#x02013;46) (<italic>n</italic> = 38)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.042</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Acute kidney injury </td><td align="center" valign="middle" rowspan="1" colspan="1">67 (65.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (55.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">33 (80.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.011</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Renal replacement therapy</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (24.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (18)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (34.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.099</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pneumothorax</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (12.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (6.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (22)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.033</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Acute respiratory distress syndrome </td><td align="center" valign="middle" rowspan="1" colspan="1">52 (51)</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (41)</td><td align="center" valign="middle" rowspan="1" colspan="1">27 (65.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.016</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pneumonia</td><td align="center" valign="middle" rowspan="1" colspan="1">96 (94.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">57 (93.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">39 (95.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pulmonary edema</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (2.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (4.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.272</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Meningoencephalitis</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2) </td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.6) </td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Intracranial hemorrhage</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1) </td><td align="center" valign="middle" rowspan="1" colspan="1">0 </td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.402</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gastrointestinal bleeding</td><td align="center" valign="middle" rowspan="1" colspan="1">36 (35.3) </td><td align="center" valign="middle" rowspan="1" colspan="1">15 (24.6) </td><td align="center" valign="middle" rowspan="1" colspan="1">21 (51.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.011</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fulminant hepatitis </td><td align="center" valign="middle" rowspan="1" colspan="1">9 (8.8) </td><td align="center" valign="middle" rowspan="1" colspan="1">6 (9.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (7.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.737</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rhabdomyolysis</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (11.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (8.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (17.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.216</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bacteremia</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (16.7) </td><td align="center" valign="middle" rowspan="1" colspan="1">11 (64.7) </td><td align="center" valign="middle" rowspan="1" colspan="1">6 (35.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bacteremia onset &#x02265; 48 h after presentation</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (11.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (11.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (12.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fungemia</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2) </td><td align="center" valign="middle" rowspan="1" colspan="1">0 </td><td align="center" valign="middle" rowspan="1" colspan="1">2 (4.9) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.159</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ECMO support</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (16.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (8.2) </td><td align="center" valign="middle" rowspan="1" colspan="1">12 (29.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.017</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duration of ECMO treatment, day, median (range)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (3&#x02013;25) (<italic>n</italic> = 17)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (5&#x02013;25) (<italic>n</italic> = 5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.5 (3&#x02013;25) (<italic>n</italic> = 12)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.958</td></tr></tbody></table><table-wrap-foot><fn><p>Data expressed as number (%) unless otherwise indicated. ECMO, Extra-corporeal membrane oxygenation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="jcm-09-01073-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">jcm-09-01073-t005_Table 5</object-id><label>Table 5</label><caption><p>Multivariate analysis of independent risk factors associated with fatality in patients with critically ill influenza.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Odds Ratio</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">95% Confidence Interval</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">High blood lactate levels</td><td align="center" valign="middle" rowspan="1" colspan="1">1.041</td><td align="center" valign="middle" rowspan="1" colspan="1">1.019&#x02013;1.064</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Adult respiratory distress syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">10.098</td><td align="center" valign="middle" rowspan="1" colspan="1">2.505&#x02013;40.714</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Acute kidney injury</td><td align="center" valign="middle" rowspan="1" colspan="1">9.019</td><td align="center" valign="middle" rowspan="1" colspan="1">1.804&#x02013;45.089</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastrointestinal bleeding</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.828</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.180&#x02013;12.415</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.025</td></tr></tbody></table></table-wrap></floats-group></article>